| Mahendra K Gupta, MD | |
|
1702 University Dr S, Fargo, ND 58103-4940 | |
| (701) 364-3300 | |
| (701) 364-8906 |
| Full Name | Mahendra K Gupta |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 36 Years |
| Location | 1702 University Dr S, Fargo, North Dakota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508899139 | NPI | - | NPPES |
| 2408951 | Other | ND | AMERICA'S PPO/ARAZ # |
| DA9011040085 | Other | ND | PREFERRED ONE # |
| 12157 | Medicaid | ND | |
| 682610500 | Medicaid | ND | |
| 3600619 | Other | ND | MEDICA # |
| 042H1GU | Other | ND | MNBS # |
| 26356 | Other | ND | NDBS # |
| 3600620 | Other | ND | MEDICA # |
| HP59530 | Other | ND | HEALTHPARTNERS # |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 9224 (North Dakota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Medical Center Fargo | Fargo, ND | Hospital |
| Chi Mercy Health | Valley city, ND | Hospital |
| Sanford Wheaton Medical Center | Wheaton, MN | Hospital |
| Perham Health | Perham, MN | Hospital |
| Jamestown Regional Medical Center | Jamestown, ND | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Medical Center Fargo | 8426967803 | 1094 |
News Archive
Aspiration among critically ill patients may often be subtle or even silent, but that doesn't mean it's insignificant.
FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.
Scientists have traced the first steps in the way some new diseases emerge, and how harmless bacteria living in insects become dangerous disease-causing bugs which can affect humans, like the plague or anthrax.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.
› Verified 1 days ago
| Entity Name | Sanford Clinic North |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942241351 PECOS PAC ID: 4284546151 Enrollment ID: O20031112000221 |
News Archive
Aspiration among critically ill patients may often be subtle or even silent, but that doesn't mean it's insignificant.
FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.
Scientists have traced the first steps in the way some new diseases emerge, and how harmless bacteria living in insects become dangerous disease-causing bugs which can affect humans, like the plague or anthrax.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.
› Verified 1 days ago
| Entity Name | Sanford Medical Center Fargo |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184917924 PECOS PAC ID: 8426967803 Enrollment ID: O20110331000495 |
News Archive
Aspiration among critically ill patients may often be subtle or even silent, but that doesn't mean it's insignificant.
FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.
Scientists have traced the first steps in the way some new diseases emerge, and how harmless bacteria living in insects become dangerous disease-causing bugs which can affect humans, like the plague or anthrax.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mahendra K Gupta, MD Po Box 6001, Fargo, ND 58108-6001 Ph: (701) 364-3300 | Mahendra K Gupta, MD 1702 University Dr S, Fargo, ND 58103-4940 Ph: (701) 364-3300 |
News Archive
Aspiration among critically ill patients may often be subtle or even silent, but that doesn't mean it's insignificant.
FerroKin BioSciences today announced the initiation of an international Phase 2 study of FBS0701, a novel once-daily iron chelator in development for the treatment of transfusional iron overload. The Phase 2 study will assess the safety, tolerability, and pharmacodynamics of FBS0701.
Scientists have traced the first steps in the way some new diseases emerge, and how harmless bacteria living in insects become dangerous disease-causing bugs which can affect humans, like the plague or anthrax.
Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has earned a $14 million clinical milestone payment from Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies. Vitae's 11beta-hydroxysteroid dehydrogenase (HSD)-1 is targeted for the treatment of diabetes and metabolic syndrome-related diseases in a strategic alliance with Boehringer Ingelheim. The payment recognizes Boehringer Ingelheim's recent advancement of a small molecule inhibitor of 11beta-HSD-1 into Phase I clinical trials.
The JC polyomavirus doesn't strike very often, but it's a mean bug that preys on people with weakened immune systems, including people with AIDS, and almost always kills them. Now an international team of scientists at Brown University, the University of T-bingen in Germany, and Imperial College in London has found a potential Achilles Heel and painted a target on it: The virus must bind to a very specific sugar molecule dangling from the side of the brain cells it attacks.
› Verified 1 days ago
Dr. Keri Lynn Crewson, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: Sanford Health, 801 Broadway North, Fargo, ND 58122 Phone: 701-234-5933 Fax: 701-234-7230 | |
Abdallah M Mansour, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 3000 32nd Ave S, Fargo, ND 58103 Phone: 701-364-8900 | |
Derek Anderson, DO Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5225 23rd Ave S, Fargo, ND 58104 Phone: 701-234-5933 | |
Gerald G Gross, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 820 4th St N, Fargo, ND 58102 Phone: 701-234-6161 | |
Paul James Carson, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-4811 Fax: 701-234-6979 | |
Howard L Russell, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 820 N 4th St, Fargo, ND 58122 Phone: 701-234-6161 Fax: 701-234-3861 | |
Dr. Emuejevoke Joseph Okoh, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 801 Broadway N, Fargo, ND 58102 Phone: 701-234-2000 |